Buffer Substances for Wound pH Stabilization and Scar Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current wound healing technologies face challenges in promoting rapid wound healing while minimizing scar formation, as existing methods often lead to skin irritation and inadequate suppression of fibrin formation and scarring, and may not be optimally effective across all phases of wound healing.
Innovation Solution
The use of buffer substances that suppress fibrin formation and crosslinking, formulated into a wound care product with a pH between 3 and 7, which stabilizes the wound environment and promotes optimal healing by inhibiting thrombin and fibrinogen activity, thereby reducing scar tissue formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If alkalizing agents are used to increase pH value in the wound, then scar formation is suppressed, but wound healing is insufficiently promoted and skin irritation occurs
Solution Approach 1:
The patent changes the pH parameter from alkaline (prior art) to acidic range (pH 2-6), fundamentally altering the chemical environment to simultaneously suppress scar formation and promote wound healing. This parameter inversion resolves the contradiction by finding an optimal acidic pH range that achieves both goals.
Solution Approach 2:
The patent uses a buffer system that dynamically maintains pH stability in the acidic range, allowing the wound environment to adapt while staying within the therapeutic pH window. The buffer capacity enables the system to resist pH changes despite wound exudate variations, ensuring consistent therapeutic effect throughout healing phases.
2Object-affected harmful factors
If buffer substances are used to stabilize pH in the wound, then fibrin formation is suppressed, but the complexity of the wound care product increases
Solution Approach 1:
The patent employs conventional, readily available buffer substances (citric acid, lactic acid, boric acid and their salts) that are inexpensive and stable, rather than complex or proprietary buffer systems. This approach suppresses fibrin formation while minimizing product complexity and cost.
Solution Approach 2:
The patent specifies a concrete pH range (2-6) and buffer capacity range (0.1-10 mmol/g), transforming the complex problem of fibrin suppression into a manageable parameter specification. This quantification simplifies the formulation process and ensures consistent therapeutic effect without excessive complexity.
3Object-affected harmful factors
If the wound environment is alkalized to inhibit transforming growth factor activity, then scar formation is reduced, but the effectiveness across all healing phases is insufficient
Solution Approach 1:
The patent employs a buffer system that maintains pH stability throughout all wound healing phases, allowing the same acidic pH environment (2-6) to be effective from the inflammatory phase through proliferation to remodeling. This dynamic stability enables versatility across all healing phases, unlike phase-specific treatments.
Solution Approach 2:
The patent inverts the conventional approach by using acidic pH (2-6) instead of alkaline pH to inhibit transforming growth factor activity and suppress scar formation. This inversion achieves the same therapeutic goal while being effective across all healing phases, not just specific phases.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances wound healing by stabilizing the pH environment, reducing fibrin formation, and minimizing scar tissue, leading to improved tissue oxygenation and reduced scarring, making it suitable for all phases of wound healing.
Implementation Method 1
buffer substances for use in treatment to suppress fibrin formation and/or fibrin crosslinking, the buffer substances forming a buffer solution with a pH between pH 3 and pH 7 after dissolution in demineralized water at 37°C
Implementation Method 2
providing a buffer solution by dissolving buffer substances in demineralized water and adjusting the pH to a value between 3 and 7
Data Source
Figure 1~3
AI summary
The invention relates to buffer substances for the phase-appropriate treatment of wounds, said treatment comprising the suppression of fibrin formation and/or fibrin cross-linking. The invention further relates to a wound dressing product containing said buffer substances to suppress fibrin formation and/or fibrin cross-linking.